BR112020015666A2

BR112020015666A2 - moduladores de espiro-lactamas de receptores nmda e usos dos mesmos

moduladores de espiro-lactamas de receptores nmda e usos dos mesmos Download PDF

Info

Publication number: BR112020015666A2
Authority: BR; Brazil
Prior art keywords: compound; group; fact; independently selected; optionally substituted
Prior art date: 2018-01-31

Application number

BR112020015666-3A

Other languages

English (en)

Portuguese (pt)

Inventor

M. Amin Khan

Original Assignee

Aptinyx Inc.

Priority date

2018-01-31

Filing date

2019-01-31

Publication date

2021-02-23

2019-01-31 Application filed by Aptinyx Inc. filed Critical Aptinyx Inc.

2021-02-23 Publication of BR112020015666A2 publication Critical patent/BR112020015666A2/pt

Links

108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 title abstract description 34
102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 title abstract description 34
150000001875 compounds Chemical class 0.000 claims abstract description 309
125000001424 substituent group Chemical group 0.000 claims description 104
-1 -C1-C6alkyl Inorganic materials 0.000 claims description 74
238000000034 method Methods 0.000 claims description 70
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 66
229910052736 halogen Inorganic materials 0.000 claims description 56
150000002367 halogens Chemical class 0.000 claims description 56
229910052739 hydrogen Inorganic materials 0.000 claims description 56
150000003839 salts Chemical class 0.000 claims description 36
229910003827 NRaRb Inorganic materials 0.000 claims description 34
229910052701 rubidium Inorganic materials 0.000 claims description 34
229910052705 radium Inorganic materials 0.000 claims description 33
125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 29
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 29
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 28
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 26
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 24
208000035475 disorder Diseases 0.000 claims description 23
125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 22
239000008194 pharmaceutical composition Substances 0.000 claims description 19
229910052757 nitrogen Inorganic materials 0.000 claims description 17
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 16
208000024827 Alzheimer disease Diseases 0.000 claims description 12
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 10
208000004296 neuralgia Diseases 0.000 claims description 10
208000021722 neuropathic pain Diseases 0.000 claims description 10
201000000980 schizophrenia Diseases 0.000 claims description 10
208000010877 cognitive disease Diseases 0.000 claims description 9
208000019901 Anxiety disease Diseases 0.000 claims description 7
230000036506 anxiety Effects 0.000 claims description 7
229910052731 fluorine Inorganic materials 0.000 claims description 7
208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims description 6
208000028698 Cognitive impairment Diseases 0.000 claims description 6
208000030886 Traumatic Brain injury Diseases 0.000 claims description 6
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 6
230000009529 traumatic brain injury Effects 0.000 claims description 6
125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 4
208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims description 4
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 4
208000029726 Neurodevelopmental disease Diseases 0.000 claims description 4
208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims description 4
239000011737 fluorine Substances 0.000 claims description 4
208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 claims description 4
239000000546 pharmaceutical excipient Substances 0.000 claims description 4
230000003976 synaptic dysfunction Effects 0.000 claims description 4
125000004011 3 membered carbocyclic group Chemical group 0.000 claims description 3
208000019695 Migraine disease Diseases 0.000 claims description 3
206010027599 migraine Diseases 0.000 claims description 3
125000003003 spiro group Chemical group 0.000 claims description 3
238000007911 parenteral administration Methods 0.000 claims description 2
238000011200 topical administration Methods 0.000 claims description 2
230000000694 effects Effects 0.000 abstract description 10
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 294
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 217
IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 204
239000000243 solution Substances 0.000 description 145
239000011541 reaction mixture Substances 0.000 description 142
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 141
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 130
230000002829 reductive effect Effects 0.000 description 127
238000003786 synthesis reaction Methods 0.000 description 127
230000015572 biosynthetic process Effects 0.000 description 124
239000007858 starting material Substances 0.000 description 117
238000005160 1H NMR spectroscopy Methods 0.000 description 107
238000004809 thin layer chromatography Methods 0.000 description 107
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 98
238000004895 liquid chromatography mass spectrometry Methods 0.000 description 92
239000000203 mixture Substances 0.000 description 91
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 87
239000007787 solid Substances 0.000 description 78
235000019439 ethyl acetate Nutrition 0.000 description 68
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 63
239000012044 organic layer Substances 0.000 description 63
239000007832 Na2SO4 Substances 0.000 description 62
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 62
229910052938 sodium sulfate Inorganic materials 0.000 description 62
235000011152 sodium sulphate Nutrition 0.000 description 62
238000004440 column chromatography Methods 0.000 description 55
238000004128 high performance liquid chromatography Methods 0.000 description 53
238000004296 chiral HPLC Methods 0.000 description 44
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 43
239000007788 liquid Substances 0.000 description 42
239000012299 nitrogen atmosphere Substances 0.000 description 41
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 38
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 38
230000014759 maintenance of location Effects 0.000 description 37
239000012267 brine Substances 0.000 description 36
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 36
NWBHFRLYIQGEEF-UHFFFAOYSA-N tert-butyl 10-[(4-fluorophenyl)methyl]-11-oxo-1,10-diazaspiro[4.6]undec-7-ene-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCCC11CC=CCN(CC2=CC=C(F)C=C2)C1=O NWBHFRLYIQGEEF-UHFFFAOYSA-N 0.000 description 36
HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 35
238000000746 purification Methods 0.000 description 33
238000006243 chemical reaction Methods 0.000 description 32
239000003039 volatile agent Substances 0.000 description 31
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 29
229910052681 coesite Inorganic materials 0.000 description 27
229940125898 compound 5 Drugs 0.000 description 27
229910052906 cristobalite Inorganic materials 0.000 description 27
239000000377 silicon dioxide Substances 0.000 description 27
235000012239 silicon dioxide Nutrition 0.000 description 27
229910052682 stishovite Inorganic materials 0.000 description 27
229910052905 tridymite Inorganic materials 0.000 description 27
SNNIDOBQZGLNAW-FCVFOURSSA-N (3S,7aS)-7a-[(Z)-4-bromobut-2-enyl]-3-(trichloromethyl)-3,5,6,7-tetrahydropyrrolo[1,2-c][1,3]oxazol-1-one Chemical compound ClC(Cl)(Cl)[C@@H]1OC(=O)[C@@]2(C\C=C/CBr)CCCN12 SNNIDOBQZGLNAW-FCVFOURSSA-N 0.000 description 26
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 26
229940125782 compound 2 Drugs 0.000 description 25
229940126214 compound 3 Drugs 0.000 description 25
239000013058 crude material Substances 0.000 description 21
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 20
DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 20
229940125904 compound 1 Drugs 0.000 description 19
235000017557 sodium bicarbonate Nutrition 0.000 description 19
229910000030 sodium bicarbonate Inorganic materials 0.000 description 19
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 16
ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 16
239000003921 oil Substances 0.000 description 16
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 15
NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 15
241001465754 Metazoa Species 0.000 description 15
239000012298 atmosphere Substances 0.000 description 15
208000024891 symptom Diseases 0.000 description 15
SNNIDOBQZGLNAW-WJNJLFNBSA-N (3R,7aR)-7a-[(Z)-4-bromobut-2-enyl]-3-(trichloromethyl)-3,5,6,7-tetrahydropyrrolo[1,2-c][1,3]oxazol-1-one Chemical compound ClC(Cl)(Cl)[C@H]1OC(=O)[C@]2(C\C=C/CBr)CCCN12 SNNIDOBQZGLNAW-WJNJLFNBSA-N 0.000 description 14
238000002474 experimental method Methods 0.000 description 14
239000000706 filtrate Substances 0.000 description 14
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 14
GNQLAUMYASHOHE-UHFFFAOYSA-N tert-butyl 3,3-difluoro-11-oxo-1,10-diazaspiro[4.6]undec-7-ene-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CC(F)(F)CC11CC=CCNC1=O GNQLAUMYASHOHE-UHFFFAOYSA-N 0.000 description 14
JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 13
GWQBXRYSVSZLSL-UJURSFKZSA-N (3r,7as)-3-(trichloromethyl)-5,6,7,7a-tetrahydro-3h-pyrrolo[1,2-c][1,3]oxazol-1-one Chemical compound C1CCN2[C@@H](C(Cl)(Cl)Cl)OC(=O)[C@@H]21 GWQBXRYSVSZLSL-UJURSFKZSA-N 0.000 description 12
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 12
208000028017 Psychotic disease Diseases 0.000 description 12
229940024606 amino acid Drugs 0.000 description 12
235000001014 amino acid Nutrition 0.000 description 12
150000001413 amino acids Chemical class 0.000 description 12
235000019270 ammonium chloride Nutrition 0.000 description 12
238000002953 preparative HPLC Methods 0.000 description 12
239000000047 product Substances 0.000 description 12
238000012360 testing method Methods 0.000 description 12
DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 12
HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 11
238000009472 formulation Methods 0.000 description 11
229920006395 saturated elastomer Polymers 0.000 description 11
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 10
HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 10
PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 10
CBHOOMGKXCMKIR-UHFFFAOYSA-N azane;methanol Chemical compound N.OC CBHOOMGKXCMKIR-UHFFFAOYSA-N 0.000 description 10
230000001225 therapeutic effect Effects 0.000 description 10
FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 10
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 9
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
239000000556 agonist Substances 0.000 description 9
230000027455 binding Effects 0.000 description 9
238000003818 flash chromatography Methods 0.000 description 9
239000005457 ice water Substances 0.000 description 9
KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 9
239000000725 suspension Substances 0.000 description 9
NXPRYCXVFFTXOK-UHFFFAOYSA-N 2,8-diazaspiro[5.5]undecan-1-one Chemical compound O=C1NCCCC11CNCCC1 NXPRYCXVFFTXOK-UHFFFAOYSA-N 0.000 description 8
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
206010012289 Dementia Diseases 0.000 description 8
239000004471 Glycine Substances 0.000 description 8
230000002378 acidificating effect Effects 0.000 description 8
229960002449 glycine Drugs 0.000 description 8
YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 8
108090000623 proteins and genes Proteins 0.000 description 8
RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 8
206010003805 Autism Diseases 0.000 description 7
208000020706 Autistic disease Diseases 0.000 description 7
108091006146 Channels Proteins 0.000 description 7
102100029458 Glutamate receptor ionotropic, NMDA 2A Human genes 0.000 description 7
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 7
150000001204 N-oxides Chemical class 0.000 description 7
241000700159 Rattus Species 0.000 description 7
208000006011 Stroke Diseases 0.000 description 7
239000002253 acid Substances 0.000 description 7
229910052799 carbon Inorganic materials 0.000 description 7
239000002131 composite material Substances 0.000 description 7
125000001153 fluoro group Chemical group F* 0.000 description 7
229940049906 glutamate Drugs 0.000 description 7
229930195712 glutamate Natural products 0.000 description 7
235000015320 potassium carbonate Nutrition 0.000 description 7
229910000027 potassium carbonate Inorganic materials 0.000 description 7
238000010992 reflux Methods 0.000 description 7
238000003756 stirring Methods 0.000 description 7
239000006188 syrup Substances 0.000 description 7
235000020357 syrup Nutrition 0.000 description 7
KPQNVHYFQNCPBT-SECBINFHSA-N (5r)-1,10-diazaspiro[4.6]undecan-11-one Chemical compound O=C1NCCCC[C@]11NCCC1 KPQNVHYFQNCPBT-SECBINFHSA-N 0.000 description 6
RMXLHIUHKIVPAB-UPHRSURJSA-N (z)-1,4-dibromobut-2-ene Chemical compound BrC\C=C/CBr RMXLHIUHKIVPAB-UPHRSURJSA-N 0.000 description 6
VJPCXXOYSPTDTN-UHFFFAOYSA-N 1,8-diazaspiro[5.5]undecan-7-one Chemical compound O=C1NCCCC11NCCCC1 VJPCXXOYSPTDTN-UHFFFAOYSA-N 0.000 description 6
IGNANRMPQBBION-UHFFFAOYSA-N 1,9-diazaspiro[4.5]decan-10-one Chemical compound O=C1NCCCC11NCCC1 IGNANRMPQBBION-UHFFFAOYSA-N 0.000 description 6
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
101100446506 Mus musculus Fgf3 gene Proteins 0.000 description 6
101100348848 Mus musculus Notch4 gene Proteins 0.000 description 6
CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical group CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 6
125000004429 atom Chemical group 0.000 description 6
125000000753 cycloalkyl group Chemical group 0.000 description 6
UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 6
239000003814 drug Substances 0.000 description 6
238000010828 elution Methods 0.000 description 6
239000010410 layer Substances 0.000 description 6
229910052763 palladium Inorganic materials 0.000 description 6
235000018102 proteins Nutrition 0.000 description 6
102000004169 proteins and genes Human genes 0.000 description 6
239000002904 solvent Substances 0.000 description 6
239000000126 substance Substances 0.000 description 6
QFAJTMUGBGIGIF-UHFFFAOYSA-N 2,8-diazaspiro[5.6]dodecan-7-one Chemical compound C1NCCCC11C(NCCCC1)=O QFAJTMUGBGIGIF-UHFFFAOYSA-N 0.000 description 5
WDBQJSCPCGTAFG-QHCPKHFHSA-N 4,4-difluoro-N-[(1S)-3-[4-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)piperidin-1-yl]-1-pyridin-3-ylpropyl]cyclohexane-1-carboxamide Chemical compound FC1(CCC(CC1)C(=O)N[C@@H](CCN1CCC(CC1)N1C(=NN=C1C)C(C)C)C=1C=NC=CC=1)F WDBQJSCPCGTAFG-QHCPKHFHSA-N 0.000 description 5
208000030507 AIDS Diseases 0.000 description 5
208000020925 Bipolar disease Diseases 0.000 description 5
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 5
229940126062 Compound A Drugs 0.000 description 5
102100022630 Glutamate receptor ionotropic, NMDA 2B Human genes 0.000 description 5
102100022626 Glutamate receptor ionotropic, NMDA 2D Human genes 0.000 description 5
NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 5
241000124008 Mammalia Species 0.000 description 5
229930040373 Paraformaldehyde Natural products 0.000 description 5
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
238000010521 absorption reaction Methods 0.000 description 5
125000003545 alkoxy group Chemical group 0.000 description 5
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 5
229910052794 bromium Inorganic materials 0.000 description 5
239000011575 calcium Substances 0.000 description 5
125000003636 chemical group Chemical group 0.000 description 5
239000003153 chemical reaction reagent Substances 0.000 description 5
230000001684 chronic effect Effects 0.000 description 5
201000010099 disease Diseases 0.000 description 5
229940079593 drug Drugs 0.000 description 5
CQRPUKWAZPZXTO-UHFFFAOYSA-M magnesium;2-methylpropane;chloride Chemical compound [Mg+2].[Cl-].C[C-](C)C CQRPUKWAZPZXTO-UHFFFAOYSA-M 0.000 description 5
229920002866 paraformaldehyde Polymers 0.000 description 5
230000036961 partial effect Effects 0.000 description 5
238000002360 preparation method Methods 0.000 description 5
230000009467 reduction Effects 0.000 description 5
230000000707 stereoselective effect Effects 0.000 description 5
208000011580 syndromic disease Diseases 0.000 description 5
239000003981 vehicle Substances 0.000 description 5
UVKSYLIOUSYQER-VIFPVBQESA-N (5R)-1,10-diazaspiro[4.6]undec-7-en-11-one Chemical compound N1CCC[C@@]11C(NCC=CC1)=O UVKSYLIOUSYQER-VIFPVBQESA-N 0.000 description 4
ORTVZLZNOYNASJ-UPHRSURJSA-N (z)-but-2-ene-1,4-diol Chemical compound OC\C=C/CO ORTVZLZNOYNASJ-UPHRSURJSA-N 0.000 description 4
SHYIWWDIHIUYQH-UHFFFAOYSA-N 3,3-difluoro-1,10-diazaspiro[4.6]undec-7-en-11-one Chemical compound FC1(F)CNC2(C1)CC=CCNC2=O SHYIWWDIHIUYQH-UHFFFAOYSA-N 0.000 description 4
201000006474 Brain Ischemia Diseases 0.000 description 4
206010008120 Cerebral ischaemia Diseases 0.000 description 4
206010010904 Convulsion Diseases 0.000 description 4
206010012239 Delusion Diseases 0.000 description 4
101710195187 Glutamate receptor ionotropic, NMDA 2B Proteins 0.000 description 4
102100022631 Glutamate receptor ionotropic, NMDA 2C Human genes 0.000 description 4
208000010496 Heart Arrest Diseases 0.000 description 4
208000023105 Huntington disease Diseases 0.000 description 4
WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 4
108010084867 N-methyl D-aspartate receptor subtype 2A Proteins 0.000 description 4
208000002193 Pain Diseases 0.000 description 4
208000018737 Parkinson disease Diseases 0.000 description 4
230000001154 acute effect Effects 0.000 description 4
150000001576 beta-amino acids Chemical class 0.000 description 4
210000004556 brain Anatomy 0.000 description 4
125000002837 carbocyclic group Chemical group 0.000 description 4
125000004432 carbon atom Chemical group C* 0.000 description 4
206010008118 cerebral infarction Diseases 0.000 description 4
231100000868 delusion Toxicity 0.000 description 4
239000003937 drug carrier Substances 0.000 description 4
206010015037 epilepsy Diseases 0.000 description 4
XPXMKIXDFWLRAA-UHFFFAOYSA-N hydrazinide Chemical compound [NH-]N XPXMKIXDFWLRAA-UHFFFAOYSA-N 0.000 description 4
INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 4
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 4
239000003446 ligand Substances 0.000 description 4
230000003228 microsomal effect Effects 0.000 description 4
239000002480 mineral oil Substances 0.000 description 4
235000010446 mineral oil Nutrition 0.000 description 4
208000002851 paranoid schizophrenia Diseases 0.000 description 4
102000005962 receptors Human genes 0.000 description 4
108020003175 receptors Proteins 0.000 description 4
238000001953 recrystallisation Methods 0.000 description 4
230000004044 response Effects 0.000 description 4
238000010898 silica gel chromatography Methods 0.000 description 4
239000011734 sodium Substances 0.000 description 4
231100001274 therapeutic index Toxicity 0.000 description 4
HFFLGKNGCAIQMO-UHFFFAOYSA-N trichloroacetaldehyde Chemical compound ClC(Cl)(Cl)C=O HFFLGKNGCAIQMO-UHFFFAOYSA-N 0.000 description 4
VUDZSIYXZUYWSC-DBRKOABJSA-N (4r)-1-[(2r,4r,5r)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-4-hydroxy-1,3-diazinan-2-one Chemical compound FC1(F)[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)N[C@H](O)CC1 VUDZSIYXZUYWSC-DBRKOABJSA-N 0.000 description 3
KPQNVHYFQNCPBT-VIFPVBQESA-N (5S)-1,10-diazaspiro[4.6]undecan-11-one Chemical compound N1CCC[C@@]11C(NCCCC1)=O KPQNVHYFQNCPBT-VIFPVBQESA-N 0.000 description 3
JOFDSYLCZIHGGO-UHFFFAOYSA-N 4-[(4-cyclohexylphenyl)methyl-[2-[[5-(dimethylamino)naphthalen-1-yl]sulfonyl-methylamino]acetyl]amino]-2-hydroxybenzoic acid Chemical compound C1=CC=C2C(N(C)C)=CC=CC2=C1S(=O)(=O)N(C)CC(=O)N(C=1C=C(O)C(C(O)=O)=CC=1)CC(C=C1)=CC=C1C1CCCCC1 JOFDSYLCZIHGGO-UHFFFAOYSA-N 0.000 description 3
WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 3
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
ONIBWKKTOPOVIA-SCSAIBSYSA-N D-Proline Chemical compound OC(=O)[C@H]1CCCN1 ONIBWKKTOPOVIA-SCSAIBSYSA-N 0.000 description 3
201000010374 Down Syndrome Diseases 0.000 description 3
208000001914 Fragile X syndrome Diseases 0.000 description 3
101710195185 Glutamate receptor ionotropic, NMDA 2C Proteins 0.000 description 3
101710195184 Glutamate receptor ionotropic, NMDA 2D Proteins 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 3
208000026139 Memory disease Diseases 0.000 description 3
208000021384 Obsessive-Compulsive disease Diseases 0.000 description 3
OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
239000007868 Raney catalyst Substances 0.000 description 3
NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 3
229910000564 Raney nickel Inorganic materials 0.000 description 3
208000006289 Rett Syndrome Diseases 0.000 description 3
206010041243 Social avoidant behaviour Diseases 0.000 description 3
208000026911 Tuberous sclerosis complex Diseases 0.000 description 3
230000004913 activation Effects 0.000 description 3
125000000217 alkyl group Chemical group 0.000 description 3
150000003862 amino acid derivatives Chemical class 0.000 description 3
125000003277 amino group Chemical group 0.000 description 3
206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 3
239000000935 antidepressant agent Substances 0.000 description 3
229940005513 antidepressants Drugs 0.000 description 3
238000003556 assay Methods 0.000 description 3
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
239000002585 base Substances 0.000 description 3
230000008901 benefit Effects 0.000 description 3
AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 3
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 3
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
229910052791 calcium Inorganic materials 0.000 description 3
239000011203 carbon fibre reinforced carbon Substances 0.000 description 3
210000004027 cell Anatomy 0.000 description 3
239000000460 chlorine Substances 0.000 description 3
230000007423 decrease Effects 0.000 description 3
239000002612 dispersion medium Substances 0.000 description 3
239000002552 dosage form Substances 0.000 description 3
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
238000001914 filtration Methods 0.000 description 3
150000002430 hydrocarbons Chemical class 0.000 description 3
238000001727 in vivo Methods 0.000 description 3
239000004615 ingredient Substances 0.000 description 3
125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 3
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
239000000463 material Substances 0.000 description 3
230000015654 memory Effects 0.000 description 3
208000027061 mild cognitive impairment Diseases 0.000 description 3
229940078552 o-xylene Drugs 0.000 description 3
229910052760 oxygen Inorganic materials 0.000 description 3
239000001301 oxygen Substances 0.000 description 3
230000036407 pain Effects 0.000 description 3
229920000137 polyphosphoric acid Polymers 0.000 description 3
230000001242 postsynaptic effect Effects 0.000 description 3
239000000843 powder Substances 0.000 description 3
230000008569 process Effects 0.000 description 3
229960002429 proline Drugs 0.000 description 3
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
150000003254 radicals Chemical class 0.000 description 3
208000020431 spinal cord injury Diseases 0.000 description 3
230000003956 synaptic plasticity Effects 0.000 description 3
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
208000009999 tuberous sclerosis Diseases 0.000 description 3
IFDTYRKEKRSUEM-UHFFFAOYSA-N undec-2-en-6-one Chemical compound CCCCCC(=O)CCC=CC IFDTYRKEKRSUEM-UHFFFAOYSA-N 0.000 description 3
OAWXZFGKDDFTGS-BYPYZUCNSA-N (2s)-pyrrolidine-1,2-dicarboxylic acid Chemical compound OC(=O)[C@@H]1CCCN1C(O)=O OAWXZFGKDDFTGS-BYPYZUCNSA-N 0.000 description 2
GWQBXRYSVSZLSL-XINAWCOVSA-N (3s,7ar)-3-(trichloromethyl)-5,6,7,7a-tetrahydro-3h-pyrrolo[1,2-c][1,3]oxazol-1-one Chemical compound C1CCN2[C@H](C(Cl)(Cl)Cl)OC(=O)[C@H]21 GWQBXRYSVSZLSL-XINAWCOVSA-N 0.000 description 2
MHNSPTUQQIYJOT-CULRIWENSA-N (3z)-3-(6h-benzo[c][1]benzoxepin-11-ylidene)-n,n-dimethylpropan-1-amine;hydrochloride Chemical compound Cl.C1OC2=CC=CC=C2C(=C/CCN(C)C)\C2=CC=CC=C21 MHNSPTUQQIYJOT-CULRIWENSA-N 0.000 description 2
UVKSYLIOUSYQER-SECBINFHSA-N (5S)-1,10-diazaspiro[4.6]undec-7-en-11-one Chemical compound O=C1NCC=CC[C@@]11CCCN1 UVKSYLIOUSYQER-SECBINFHSA-N 0.000 description 2
RMXLHIUHKIVPAB-OWOJBTEDSA-N (e)-1,4-dibromobut-2-ene Chemical compound BrC\C=C\CBr RMXLHIUHKIVPAB-OWOJBTEDSA-N 0.000 description 2
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
MDBLJSHDESHHLR-UHFFFAOYSA-N 1,7-bis(2-methylpropanoyl)-1,7-diazaspiro[4.4]nonan-6-one Chemical compound CC(C)C(=O)N1CCC2(CCCN2C(=O)C(C)C)C1=O MDBLJSHDESHHLR-UHFFFAOYSA-N 0.000 description 2
BKMVFOKQLCHCPK-UHFFFAOYSA-N 1-[(2-methylpropan-2-yl)oxycarbonyl]azepane-2-carboxylic acid Chemical compound CC(C)(C)OC(=O)N1CCCCCC1C(O)=O BKMVFOKQLCHCPK-UHFFFAOYSA-N 0.000 description 2
SDMUWYGGSCFKSY-UHFFFAOYSA-N 1-benzyl-10-methyl-1,10-diazaspiro[4.6]undec-7-en-11-one Chemical compound CN1CC=CCC2(CCCN2CC2=CC=CC=C2)C1=O SDMUWYGGSCFKSY-UHFFFAOYSA-N 0.000 description 2
GPWFTJYWZCVUTR-UHFFFAOYSA-N 10-[(4-fluorophenyl)methyl]-1,10-diazaspiro[4.6]undec-7-en-11-one Chemical compound FC1=CC=C(CN2CC=CCC3(CCCN3)C2=O)C=C1 GPWFTJYWZCVUTR-UHFFFAOYSA-N 0.000 description 2
CQZIEDXCLQOOEH-UHFFFAOYSA-N 3-bromopropanenitrile Chemical compound BrCCC#N CQZIEDXCLQOOEH-UHFFFAOYSA-N 0.000 description 2
RVTQUNOCGRKGTN-UHFFFAOYSA-N 3-chloroazocan-2-one Chemical compound ClC1CCCCCNC1=O RVTQUNOCGRKGTN-UHFFFAOYSA-N 0.000 description 2
QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 2
YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 2
206010000117 Abnormal behaviour Diseases 0.000 description 2
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
102000009091 Amyloidogenic Proteins Human genes 0.000 description 2
108010048112 Amyloidogenic Proteins Proteins 0.000 description 2
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
206010003591 Ataxia Diseases 0.000 description 2
206010003694 Atrophy Diseases 0.000 description 2
241000283690 Bos taurus Species 0.000 description 2
208000003174 Brain Neoplasms Diseases 0.000 description 2
241000282472 Canis lupus familiaris Species 0.000 description 2
208000009810 Catatonic Schizophrenia Diseases 0.000 description 2
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
102100032373 Coiled-coil domain-containing protein 85B Human genes 0.000 description 2
229930182820 D-proline Natural products 0.000 description 2
208000024254 Delusional disease Diseases 0.000 description 2
HCYAFALTSJYZDH-UHFFFAOYSA-N Desimpramine Chemical compound C1CC2=CC=CC=C2N(CCCNC)C2=CC=CC=C21 HCYAFALTSJYZDH-UHFFFAOYSA-N 0.000 description 2
YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical group [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 2
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
208000032131 Diabetic Neuropathies Diseases 0.000 description 2
206010012689 Diabetic retinopathy Diseases 0.000 description 2
208000001495 Disorganized Schizophrenia Diseases 0.000 description 2
206010052804 Drug tolerance Diseases 0.000 description 2
208000012661 Dyskinesia Diseases 0.000 description 2
241000283086 Equidae Species 0.000 description 2
241000282326 Felis catus Species 0.000 description 2
208000001640 Fibromyalgia Diseases 0.000 description 2
208000010412 Glaucoma Diseases 0.000 description 2
208000004547 Hallucinations Diseases 0.000 description 2
241000282412 Homo Species 0.000 description 2
101000868814 Homo sapiens Coiled-coil domain-containing protein 85B Proteins 0.000 description 2
208000013016 Hypoglycemia Diseases 0.000 description 2
208000030990 Impulse-control disease Diseases 0.000 description 2
206010021750 Infantile Spasms Diseases 0.000 description 2
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 2
208000020358 Learning disease Diseases 0.000 description 2
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 2
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
208000019022 Mood disease Diseases 0.000 description 2
208000001089 Multiple system atrophy Diseases 0.000 description 2
241000699670 Mus sp. Species 0.000 description 2
208000007101 Muscle Cramp Diseases 0.000 description 2
208000008238 Muscle Spasticity Diseases 0.000 description 2
206010028570 Myelopathy Diseases 0.000 description 2
208000002033 Myoclonus Diseases 0.000 description 2
LFZAGIJXANFPFN-UHFFFAOYSA-N N-[3-[4-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)piperidin-1-yl]-1-thiophen-2-ylpropyl]acetamide Chemical compound C(C)(C)C1=NN=C(N1C1CCN(CC1)CCC(C=1SC=CC=1)NC(C)=O)C LFZAGIJXANFPFN-UHFFFAOYSA-N 0.000 description 2
238000005481 NMR spectroscopy Methods 0.000 description 2
108020002076 NR2 subfamily Proteins 0.000 description 2
102000038100 NR2 subfamily Human genes 0.000 description 2
108091008644 NR2D Proteins 0.000 description 2
208000003435 Optic Neuritis Diseases 0.000 description 2
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 2
229910019142 PO4 Inorganic materials 0.000 description 2
241001494479 Pecora Species 0.000 description 2
OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
206010034912 Phobia Diseases 0.000 description 2
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
208000017442 Retinal disease Diseases 0.000 description 2
206010038923 Retinopathy Diseases 0.000 description 2
101000767160 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) Intracellular protein transport protein USO1 Proteins 0.000 description 2
208000036755 Schizophrenia simple Diseases 0.000 description 2
208000036754 Schizophrenia, catatonic type Diseases 0.000 description 2
208000036752 Schizophrenia, paranoid type Diseases 0.000 description 2
208000036750 Schizophrenia, residual type Diseases 0.000 description 2
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
208000005392 Spasm Diseases 0.000 description 2
241000282887 Suidae Species 0.000 description 2
208000000323 Tourette Syndrome Diseases 0.000 description 2
208000016620 Tourette disease Diseases 0.000 description 2
206010046543 Urinary incontinence Diseases 0.000 description 2
150000007513 acids Chemical class 0.000 description 2
230000009471 action Effects 0.000 description 2
239000013543 active substance Substances 0.000 description 2
230000008484 agonism Effects 0.000 description 2
150000001370 alpha-amino acid derivatives Chemical class 0.000 description 2
235000008206 alpha-amino acids Nutrition 0.000 description 2
150000001450 anions Chemical class 0.000 description 2
230000008485 antagonism Effects 0.000 description 2
239000005557 antagonist Substances 0.000 description 2
230000001430 anti-depressive effect Effects 0.000 description 2
239000000164 antipsychotic agent Substances 0.000 description 2
229940005529 antipsychotics Drugs 0.000 description 2
229940009098 aspartate Drugs 0.000 description 2
CJYXCQLOZNIMFP-UHFFFAOYSA-N azocan-2-one Chemical compound O=C1CCCCCCN1 CJYXCQLOZNIMFP-UHFFFAOYSA-N 0.000 description 2
230000006399 behavior Effects 0.000 description 2
229940077388 benzenesulfonate Drugs 0.000 description 2
SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 2
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
ZOKIXFGMWAHYDQ-UHFFFAOYSA-N but-2-ene-2,3-diol Chemical compound CC(O)=C(C)O ZOKIXFGMWAHYDQ-UHFFFAOYSA-N 0.000 description 2
150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
206010007776 catatonia Diseases 0.000 description 2
125000002091 cationic group Chemical group 0.000 description 2
150000001768 cations Chemical class 0.000 description 2
210000000170 cell membrane Anatomy 0.000 description 2
210000003169 central nervous system Anatomy 0.000 description 2
208000015114 central nervous system disease Diseases 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
238000002512 chemotherapy Methods 0.000 description 2
238000004587 chromatography analysis Methods 0.000 description 2
238000000576 coating method Methods 0.000 description 2
238000013270 controlled release Methods 0.000 description 2
239000006071 cream Substances 0.000 description 2
CGZZMOTZOONQIA-UHFFFAOYSA-N cycloheptanone Chemical compound O=C1CCCCCC1 CGZZMOTZOONQIA-UHFFFAOYSA-N 0.000 description 2
238000010908 decantation Methods 0.000 description 2
230000006735 deficit Effects 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
NKLCNNUWBJBICK-UHFFFAOYSA-N dess–martin periodinane Chemical compound C1=CC=C2I(OC(=O)C)(OC(C)=O)(OC(C)=O)OC(=O)C2=C1 NKLCNNUWBJBICK-UHFFFAOYSA-N 0.000 description 2
229910052805 deuterium Inorganic materials 0.000 description 2
238000011161 development Methods 0.000 description 2
230000018109 developmental process Effects 0.000 description 2
LVTYICIALWPMFW-UHFFFAOYSA-N diisopropanolamine Chemical compound CC(O)CNCC(C)O LVTYICIALWPMFW-UHFFFAOYSA-N 0.000 description 2
229940043279 diisopropylamine Drugs 0.000 description 2
239000006185 dispersion Substances 0.000 description 2
238000009826 distribution Methods 0.000 description 2
PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 2
230000008030 elimination Effects 0.000 description 2
238000003379 elimination reaction Methods 0.000 description 2
239000000839 emulsion Substances 0.000 description 2
230000002461 excitatory amino acid Effects 0.000 description 2
239000003257 excitatory amino acid Substances 0.000 description 2
238000012048 forced swim test Methods 0.000 description 2
230000026781 habituation Effects 0.000 description 2
108091008634 hepatocyte nuclear factors 4 Proteins 0.000 description 2
125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
239000001257 hydrogen Substances 0.000 description 2
125000004435 hydrogen atom Chemical class [H]* 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 2
230000002218 hypoglycaemic effect Effects 0.000 description 2
230000006872 improvement Effects 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
239000000543 intermediate Substances 0.000 description 2
230000000302 ischemic effect Effects 0.000 description 2
QTBFPMKWQKYFLR-UHFFFAOYSA-N isobutyl chloride Chemical compound CC(C)CCl QTBFPMKWQKYFLR-UHFFFAOYSA-N 0.000 description 2
230000008449 language Effects 0.000 description 2
230000013016 learning Effects 0.000 description 2
201000003723 learning disability Diseases 0.000 description 2
229910052744 lithium Inorganic materials 0.000 description 2
DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 2
230000027928 long-term synaptic potentiation Effects 0.000 description 2
208000024714 major depressive disease Diseases 0.000 description 2
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
230000003340 mental effect Effects 0.000 description 2
125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 2
150000007522 mineralic acids Chemical class 0.000 description 2
201000006417 multiple sclerosis Diseases 0.000 description 2
MZRVEZGGRBJDDB-UHFFFAOYSA-N n-Butyllithium Substances [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
OENGSNXUALAIFP-UHFFFAOYSA-N n-cycloheptylidenehydroxylamine Chemical compound ON=C1CCCCCC1 OENGSNXUALAIFP-UHFFFAOYSA-N 0.000 description 2
125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
230000004770 neurodegeneration Effects 0.000 description 2
230000016273 neuron death Effects 0.000 description 2
230000007935 neutral effect Effects 0.000 description 2
238000004305 normal phase HPLC Methods 0.000 description 2
150000007524 organic acids Chemical class 0.000 description 2
235000005985 organic acids Nutrition 0.000 description 2
125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 2
208000033808 peripheral neuropathy Diseases 0.000 description 2
JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 description 2
208000019899 phobic disease Diseases 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
239000010452 phosphate Substances 0.000 description 2
229910052698 phosphorus Inorganic materials 0.000 description 2
239000011574 phosphorus Substances 0.000 description 2
UHZYTMXLRWXGPK-UHFFFAOYSA-N phosphorus pentachloride Chemical compound ClP(Cl)(Cl)(Cl)Cl UHZYTMXLRWXGPK-UHFFFAOYSA-N 0.000 description 2
229920000642 polymer Polymers 0.000 description 2
208000028173 post-traumatic stress disease Diseases 0.000 description 2
238000012545 processing Methods 0.000 description 2
201000002212 progressive supranuclear palsy Diseases 0.000 description 2
208000020016 psychiatric disease Diseases 0.000 description 2
GIBQQARAXHVEGD-BSOLPCOYSA-N rapastinel Chemical compound C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)N[C@@H]([C@@H](C)O)C(N)=O)CCC1 GIBQQARAXHVEGD-BSOLPCOYSA-N 0.000 description 2
229930195734 saturated hydrocarbon Natural products 0.000 description 2
230000000698 schizophrenic effect Effects 0.000 description 2
125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
239000011669 selenium Substances 0.000 description 2
230000035945 sensitivity Effects 0.000 description 2
208000019116 sleep disease Diseases 0.000 description 2
208000020685 sleep-wake disease Diseases 0.000 description 2
239000001632 sodium acetate Substances 0.000 description 2
235000017281 sodium acetate Nutrition 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
208000018198 spasticity Diseases 0.000 description 2
238000012453 sprague-dawley rat model Methods 0.000 description 2
201000009032 substance abuse Diseases 0.000 description 2
231100000736 substance abuse Toxicity 0.000 description 2
208000011117 substance-related disease Diseases 0.000 description 2
230000000946 synaptic effect Effects 0.000 description 2
230000009885 systemic effect Effects 0.000 description 2
239000008399 tap water Substances 0.000 description 2
235000020679 tap water Nutrition 0.000 description 2
229940095064 tartrate Drugs 0.000 description 2
WORXFGQRMYPBKV-UHFFFAOYSA-N tert-butyl 10-methyl-11-oxo-1,10-diazaspiro[4.6]undec-7-ene-1-carboxylate Chemical compound CN1CC=CCC2(CCCN2C(=O)OC(C)(C)C)C1=O WORXFGQRMYPBKV-UHFFFAOYSA-N 0.000 description 2
SZTGSYGTTYIMBS-UHFFFAOYSA-N tert-butyl 3-oxo-2,5-diazaspiro[3.6]decane-5-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCCCCC11CNC1=O SZTGSYGTTYIMBS-UHFFFAOYSA-N 0.000 description 2
210000001519 tissue Anatomy 0.000 description 2
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
230000009466 transformation Effects 0.000 description 2
PHLBKPHSAVXXEF-UHFFFAOYSA-N trazodone Chemical compound ClC1=CC=CC(N2CCN(CCCN3C(N4C=CC=CC4=N3)=O)CC2)=C1 PHLBKPHSAVXXEF-UHFFFAOYSA-N 0.000 description 2
AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 description 1
LSPHULWDVZXLIL-UHFFFAOYSA-N (+/-)-Camphoric acid Chemical compound CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
KTGRHKOEFSJQNS-BDQAORGHSA-N (1s)-1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-3h-2-benzofuran-5-carbonitrile;oxalic acid Chemical compound OC(=O)C(O)=O.C1([C@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 KTGRHKOEFSJQNS-BDQAORGHSA-N 0.000 description 1
MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
VQJGUUHKSTYEGE-GCYSTPHZSA-N (2S,4R)-4-hydroxypyrrolidine-2-carboxylic acid Chemical compound N1[C@H](C(=O)O)C[C@@H](O)C1.N1[C@H](C(=O)O)C[C@@H](O)C1.N1[C@H](C(=O)O)C[C@@H](O)C1 VQJGUUHKSTYEGE-GCYSTPHZSA-N 0.000 description 1
HHDQVBSXYDRQGD-DMTCNVIQSA-N (2s,4r)-4-hydroxypyrrolidine-1,2-dicarboxylic acid Chemical compound O[C@@H]1C[C@@H](C(O)=O)N(C(O)=O)C1 HHDQVBSXYDRQGD-DMTCNVIQSA-N 0.000 description 1
125000006273 (C1-C3) alkyl group Chemical group 0.000 description 1
125000006274 (C1-C3)alkoxy group Chemical group 0.000 description 1
125000000229 (C1-C4)alkoxy group Chemical group 0.000 description 1
125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 1
GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 1
XJLSEXAGTJCILF-RXMQYKEDSA-N (R)-nipecotic acid zwitterion Chemical compound OC(=O)[C@@H]1CCCNC1 XJLSEXAGTJCILF-RXMQYKEDSA-N 0.000 description 1
VSWBSWWIRNCQIJ-GJZGRUSLSA-N (R,R)-asenapine Chemical compound O1C2=CC=CC=C2[C@@H]2CN(C)C[C@H]2C2=CC(Cl)=CC=C21 VSWBSWWIRNCQIJ-GJZGRUSLSA-N 0.000 description 1
ZEUITGRIYCTCEM-KRWDZBQOSA-N (S)-duloxetine Chemical compound C1([C@@H](OC=2C3=CC=CC=C3C=CC=2)CCNC)=CC=CS1 ZEUITGRIYCTCEM-KRWDZBQOSA-N 0.000 description 1
RHSRKUWUSKZXJP-UHFFFAOYSA-N 1,10-diazaspiro[4.6]undec-7-en-11-one 2,2,2-trifluoroacetaldehyde Chemical compound FC(F)(F)C=O.O=C1NCC=CCC11CCCN1 RHSRKUWUSKZXJP-UHFFFAOYSA-N 0.000 description 1
VEFLKXRACNJHOV-UHFFFAOYSA-N 1,3-dibromopropane Chemical compound BrCCCBr VEFLKXRACNJHOV-UHFFFAOYSA-N 0.000 description 1
ULTHEAFYOOPTTB-UHFFFAOYSA-N 1,4-dibromobutane Chemical compound BrCCCCBr ULTHEAFYOOPTTB-UHFFFAOYSA-N 0.000 description 1
150000000190 1,4-diols Chemical class 0.000 description 1
KSQRQLBTULNMJS-UHFFFAOYSA-N 1,7-diazaspiro[4.4]nonan-6-one Chemical compound O=C1NCCC11NCCC1 KSQRQLBTULNMJS-UHFFFAOYSA-N 0.000 description 1
CFZOMZLEKQEZRX-UHFFFAOYSA-N 1-(2-methylpropanoyl)-1,10-diazaspiro[4.6]undec-7-en-11-one Chemical compound CC(C)C(=O)N1CCCC11CC=CCNC1=O CFZOMZLEKQEZRX-UHFFFAOYSA-N 0.000 description 1
UVQWOCYKKRDUQF-UHFFFAOYSA-N 1-(2-methylpropanoyl)-1,7-diazaspiro[4.4]nonan-6-one Chemical compound CC(C)C(=O)N1CCCC11CCNC1=O UVQWOCYKKRDUQF-UHFFFAOYSA-N 0.000 description 1
SSNOPSBAGAFUFV-UHFFFAOYSA-N 1-(2-methylpropyl)-1,10-diazaspiro[4.6]undec-7-en-11-one Chemical compound CC(C)CN1CCCC11CC=CCNC1=O SSNOPSBAGAFUFV-UHFFFAOYSA-N 0.000 description 1
XLUORDAJLWEGLV-UHFFFAOYSA-N 1-[(4-fluorophenyl)methyl]-1,10-diazaspiro[4.6]undec-7-en-11-one Chemical compound FC1=CC=C(CN2CCCC22CC=CCNC2=O)C=C1 XLUORDAJLWEGLV-UHFFFAOYSA-N 0.000 description 1
WIHMBLDNRMIGDW-UHFFFAOYSA-N 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-3h-2-benzofuran-5-carbonitrile;hydron;bromide Chemical compound [Br-].O1CC2=CC(C#N)=CC=C2C1(CCC[NH+](C)C)C1=CC=C(F)C=C1 WIHMBLDNRMIGDW-UHFFFAOYSA-N 0.000 description 1
KTTXTQUFBDOZSW-UHFFFAOYSA-N 1-acetyl-1,10-diazaspiro[4.6]undec-7-en-11-one Chemical compound CC(=O)N1CCCC11CC=CCNC1=O KTTXTQUFBDOZSW-UHFFFAOYSA-N 0.000 description 1
CSDLZAAMTKXUSI-UHFFFAOYSA-N 1-benzyl-1,10-diazaspiro[4.6]undec-7-en-11-one Chemical compound O=C1NCC=CCC11CCCN1CC1=CC=CC=C1 CSDLZAAMTKXUSI-UHFFFAOYSA-N 0.000 description 1
BTUGGGLMQBJCBN-UHFFFAOYSA-N 1-iodo-2-methylpropane Chemical compound CC(C)CI BTUGGGLMQBJCBN-UHFFFAOYSA-N 0.000 description 1
NPSOSEQIDSDBBF-UHFFFAOYSA-N 1-methyl-1,10-diazaspiro[4.6]undec-7-en-11-one Chemical compound CN1CCCC11CC=CCNC1=O NPSOSEQIDSDBBF-UHFFFAOYSA-N 0.000 description 1
UPBHYYJZVWZCOZ-UHFFFAOYSA-N 1-o-tert-butyl 2-o-methyl 4-oxopyrrolidine-1,2-dicarboxylate Chemical compound COC(=O)C1CC(=O)CN1C(=O)OC(C)(C)C UPBHYYJZVWZCOZ-UHFFFAOYSA-N 0.000 description 1
SLPFKKMDHRUNRM-UHFFFAOYSA-N 1-o-tert-butyl 2-o-methyl azepane-1,2-dicarboxylate Chemical compound COC(=O)C1CCCCCN1C(=O)OC(C)(C)C SLPFKKMDHRUNRM-UHFFFAOYSA-N 0.000 description 1
PVMJFJDVCVNWQN-UHFFFAOYSA-N 1-o-tert-butyl 2-o-methyl piperidine-1,2-dicarboxylate Chemical compound COC(=O)C1CCCCN1C(=O)OC(C)(C)C PVMJFJDVCVNWQN-UHFFFAOYSA-N 0.000 description 1
LYYJQMCPEHXOEW-UHFFFAOYSA-N 1-o-tert-butyl 3-o-methyl piperidine-1,3-dicarboxylate Chemical compound COC(=O)C1CCCN(C(=O)OC(C)(C)C)C1 LYYJQMCPEHXOEW-UHFFFAOYSA-N 0.000 description 1
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
RUARPYLSIVFTMD-UHFFFAOYSA-N 10-benzyl-1,10-diazaspiro[4.6]undec-7-en-11-one Chemical compound O=C1N(CC2=CC=CC=C2)CC=CCC11CCCN1 RUARPYLSIVFTMD-UHFFFAOYSA-N 0.000 description 1
WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 1
JUIKUQOUMZUFQT-UHFFFAOYSA-N 2-bromoacetamide Chemical compound NC(=O)CBr JUIKUQOUMZUFQT-UHFFFAOYSA-N 0.000 description 1
REXUYBKPWIPONM-UHFFFAOYSA-N 2-bromoacetonitrile Chemical compound BrCC#N REXUYBKPWIPONM-UHFFFAOYSA-N 0.000 description 1
125000004918 2-methyl-2-pentyl group Chemical group CC(C)(CCC)* 0.000 description 1
125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
DGMOBVGABMBZSB-UHFFFAOYSA-N 2-methylpropanoyl chloride Chemical compound CC(C)C(Cl)=O DGMOBVGABMBZSB-UHFFFAOYSA-N 0.000 description 1
229940080296 2-naphthalenesulfonate Drugs 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-M 3-carboxy-2,3-dihydroxypropanoate Chemical compound OC(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-M 0.000 description 1
125000004917 3-methyl-2-butyl group Chemical group CC(C(C)*)C 0.000 description 1
125000004919 3-methyl-2-pentyl group Chemical group CC(C(C)*)CC 0.000 description 1
PMXMIIMHBWHSKN-UHFFFAOYSA-N 3-{2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl}-9-hydroxy-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCC(O)C4=NC=3C)=NOC2=C1 PMXMIIMHBWHSKN-UHFFFAOYSA-N 0.000 description 1
102100035923 4-aminobutyrate aminotransferase, mitochondrial Human genes 0.000 description 1
125000004920 4-methyl-2-pentyl group Chemical group CC(CC(C)*)C 0.000 description 1
XKFPYPQQHFEXRZ-UHFFFAOYSA-N 5-methyl-N'-(phenylmethyl)-3-isoxazolecarbohydrazide Chemical compound O1C(C)=CC(C(=O)NNCC=2C=CC=CC=2)=N1 XKFPYPQQHFEXRZ-UHFFFAOYSA-N 0.000 description 1
FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
101150037123 APOE gene Proteins 0.000 description 1
208000017194 Affective disease Diseases 0.000 description 1
208000000044 Amnesia Diseases 0.000 description 1
102000013455 Amyloid beta-Peptides Human genes 0.000 description 1
108010090849 Amyloid beta-Peptides Proteins 0.000 description 1
208000009575 Angelman syndrome Diseases 0.000 description 1
102100029470 Apolipoprotein E Human genes 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
CEUORZQYGODEFX-UHFFFAOYSA-N Aripirazole Chemical compound ClC1=CC=CC(N2CCN(CCCCOC=3C=C4NC(=O)CCC4=CC=3)CC2)=C1Cl CEUORZQYGODEFX-UHFFFAOYSA-N 0.000 description 1
DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
208000008035 Back Pain Diseases 0.000 description 1
208000021465 Brief psychotic disease Diseases 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
206010058019 Cancer Pain Diseases 0.000 description 1
239000004215 Carbon black (E152) Substances 0.000 description 1
OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
208000009132 Catalepsy Diseases 0.000 description 1
241000700198 Cavia Species 0.000 description 1
208000015879 Cerebellar disease Diseases 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
208000000094 Chronic Pain Diseases 0.000 description 1
GDLIGKIOYRNHDA-UHFFFAOYSA-N Clomipramine Chemical compound C1CC2=CC=C(Cl)C=C2N(CCCN(C)C)C2=CC=CC=C21 GDLIGKIOYRNHDA-UHFFFAOYSA-N 0.000 description 1
102000008186 Collagen Human genes 0.000 description 1
108010035532 Collagen Proteins 0.000 description 1
208000013586 Complex regional pain syndrome type 1 Diseases 0.000 description 1
102100034746 Cyclin-dependent kinase-like 5 Human genes 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
206010012335 Dependence Diseases 0.000 description 1
206010012374 Depressed mood Diseases 0.000 description 1
208000020401 Depressive disease Diseases 0.000 description 1
206010013754 Drug withdrawal syndrome Diseases 0.000 description 1
208000000059 Dyspnea Diseases 0.000 description 1
206010013975 Dyspnoeas Diseases 0.000 description 1
LFMYNZPAVPMEGP-PIDGMYBPSA-N Fluvoxamine maleate Chemical compound OC(=O)\C=C/C(O)=O.COCCCC\C(=N/OCCN)C1=CC=C(C(F)(F)F)C=C1 LFMYNZPAVPMEGP-PIDGMYBPSA-N 0.000 description 1
201000011240 Frontotemporal dementia Diseases 0.000 description 1
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
102000017692 GABRA5 Human genes 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
102100039289 Glial fibrillary acidic protein Human genes 0.000 description 1
101710193519 Glial fibrillary acidic protein Proteins 0.000 description 1
239000007821 HATU Substances 0.000 description 1
206010019070 Hallucination, auditory Diseases 0.000 description 1
206010019233 Headaches Diseases 0.000 description 1
101001000686 Homo sapiens 4-aminobutyrate aminotransferase, mitochondrial Proteins 0.000 description 1
101000945692 Homo sapiens Cyclin-dependent kinase-like 5 Proteins 0.000 description 1
101001001388 Homo sapiens Gamma-aminobutyric acid receptor subunit alpha-5 Proteins 0.000 description 1
101001125242 Homo sapiens Glutamate receptor ionotropic, NMDA 2A Proteins 0.000 description 1
101001108436 Homo sapiens Neurexin-1 Proteins 0.000 description 1
101001108433 Homo sapiens Neurexin-1-beta Proteins 0.000 description 1
101000603173 Homo sapiens Neuroligin-2 Proteins 0.000 description 1
101000603172 Homo sapiens Neuroligin-3 Proteins 0.000 description 1
101000745167 Homo sapiens Neuronal acetylcholine receptor subunit alpha-4 Proteins 0.000 description 1
101001099423 Homo sapiens Proenkephalin-A Proteins 0.000 description 1
101000828537 Homo sapiens Synaptic functional regulator FMR1 Proteins 0.000 description 1
101000772888 Homo sapiens Ubiquitin-protein ligase E3A Proteins 0.000 description 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
206010061598 Immunodeficiency Diseases 0.000 description 1
208000029462 Immunodeficiency disease Diseases 0.000 description 1
102000004310 Ion Channels Human genes 0.000 description 1
108090000862 Ion Channels Proteins 0.000 description 1
XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 1
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
229930182821 L-proline Natural products 0.000 description 1
AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
208000009829 Lewy Body Disease Diseases 0.000 description 1
201000002832 Lewy body dementia Diseases 0.000 description 1
229920005479 Lucite® Polymers 0.000 description 1
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
208000024889 MECP2 duplication syndrome Diseases 0.000 description 1
101150083522 MECP2 gene Proteins 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
102100039124 Methyl-CpG-binding protein 2 Human genes 0.000 description 1
206010027940 Mood altered Diseases 0.000 description 1
208000008770 Multiple Hamartoma Syndrome Diseases 0.000 description 1
RTHCYVBBDHJXIQ-UHFFFAOYSA-N N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine Chemical compound C=1C=CC=CC=1C(CCNC)OC1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-UHFFFAOYSA-N 0.000 description 1
229910002651 NO3 Inorganic materials 0.000 description 1
206010028813 Nausea Diseases 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
208000028389 Nerve injury Diseases 0.000 description 1
102100021582 Neurexin-1-beta Human genes 0.000 description 1
208000009905 Neurofibromatoses Diseases 0.000 description 1
208000003019 Neurofibromatosis 1 Diseases 0.000 description 1
208000024834 Neurofibromatosis type 1 Diseases 0.000 description 1
102000010196 Neuroligin Human genes 0.000 description 1
108050001755 Neuroligin Proteins 0.000 description 1
102100038939 Neuroligin-2 Human genes 0.000 description 1
102100038940 Neuroligin-3 Human genes 0.000 description 1
102100039909 Neuronal acetylcholine receptor subunit alpha-4 Human genes 0.000 description 1
101100030361 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) pph-3 gene Proteins 0.000 description 1
PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
206010057852 Nicotine dependence Diseases 0.000 description 1
NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
PHVGLTMQBUFIQQ-UHFFFAOYSA-N Nortryptiline Chemical compound C1CC2=CC=CC=C2C(=CCCNC)C2=CC=CC=C21 PHVGLTMQBUFIQQ-UHFFFAOYSA-N 0.000 description 1
208000026251 Opioid-Related disease Diseases 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
201000010917 PTEN hamartoma tumor syndrome Diseases 0.000 description 1
206010033557 Palpitations Diseases 0.000 description 1
208000004983 Phantom Limb Diseases 0.000 description 1
206010056238 Phantom pain Diseases 0.000 description 1
RMUCZJUITONUFY-UHFFFAOYSA-N Phenelzine Chemical compound NNCCC1=CC=CC=C1 RMUCZJUITONUFY-UHFFFAOYSA-N 0.000 description 1
229920002732 Polyanhydride Polymers 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
229920000954 Polyglycolide Polymers 0.000 description 1
241000183024 Populus tremula Species 0.000 description 1
208000008348 Post-Concussion Syndrome Diseases 0.000 description 1
206010036376 Postherpetic Neuralgia Diseases 0.000 description 1
201000009916 Postpartum depression Diseases 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
208000027030 Premenstrual dysphoric disease Diseases 0.000 description 1
206010036618 Premenstrual syndrome Diseases 0.000 description 1
241000288906 Primates Species 0.000 description 1
102100038931 Proenkephalin-A Human genes 0.000 description 1
102100024622 Proenkephalin-B Human genes 0.000 description 1
102000001708 Protein Isoforms Human genes 0.000 description 1
108010029485 Protein Isoforms Proteins 0.000 description 1
208000033876 Proximal Xq28 duplication syndrome Diseases 0.000 description 1
201000001947 Reflex Sympathetic Dystrophy Diseases 0.000 description 1
108010038912 Retinoid X Receptors Proteins 0.000 description 1
241000283984 Rodentia Species 0.000 description 1
102100030681 SH3 and multiple ankyrin repeat domains protein 3 Human genes 0.000 description 1
101710101741 SH3 and multiple ankyrin repeat domains protein 3 Proteins 0.000 description 1
208000036753 Schizophrenia, disorganised type Diseases 0.000 description 1
208000024791 Schizotypal Personality disease Diseases 0.000 description 1
208000008765 Sciatica Diseases 0.000 description 1
BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
208000019568 Shared Paranoid disease Diseases 0.000 description 1
XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
206010041250 Social phobia Diseases 0.000 description 1
208000010513 Stupor Diseases 0.000 description 1
208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
231100000643 Substance intoxication Toxicity 0.000 description 1
208000011963 Substance-induced psychotic disease Diseases 0.000 description 1
231100000393 Substance-induced psychotic disorder Toxicity 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
102100023532 Synaptic functional regulator FMR1 Human genes 0.000 description 1
229920002253 Tannate Polymers 0.000 description 1
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
239000004473 Threonine Substances 0.000 description 1
208000025569 Tobacco Use disease Diseases 0.000 description 1
206010070863 Toxicity to various agents Diseases 0.000 description 1
229940123445 Tricyclic antidepressant Drugs 0.000 description 1
206010044688 Trisomy 21 Diseases 0.000 description 1
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
102100030434 Ubiquitin-protein ligase E3A Human genes 0.000 description 1
KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
201000004810 Vascular dementia Diseases 0.000 description 1
241000700605 Viruses Species 0.000 description 1
206010047853 Waxy flexibility Diseases 0.000 description 1
201000006791 West syndrome Diseases 0.000 description 1
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
BKPRVQDIOGQWTG-ICOOEGOYSA-N [(1s,2r)-2-phenylcyclopropyl]azanium;[(1r,2s)-2-phenylcyclopropyl]azanium;sulfate Chemical compound [O-]S([O-])(=O)=O.[NH3+][C@H]1C[C@@H]1C1=CC=CC=C1.[NH3+][C@@H]1C[C@H]1C1=CC=CC=C1 BKPRVQDIOGQWTG-ICOOEGOYSA-N 0.000 description 1
QQIRAVWVGBTHMJ-UHFFFAOYSA-N [dimethyl-(trimethylsilylamino)silyl]methane;lithium Chemical compound [Li].C[Si](C)(C)N[Si](C)(C)C QQIRAVWVGBTHMJ-UHFFFAOYSA-N 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
229940022663 acetate Drugs 0.000 description 1
125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
230000002411 adverse Effects 0.000 description 1
230000007000 age related cognitive decline Effects 0.000 description 1
229960003767 alanine Drugs 0.000 description 1
235000004279 alanine Nutrition 0.000 description 1
229940072056 alginate Drugs 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
229910052783 alkali metal Inorganic materials 0.000 description 1
150000001340 alkali metals Chemical class 0.000 description 1
150000001447 alkali salts Chemical class 0.000 description 1
229910052784 alkaline earth metal Inorganic materials 0.000 description 1
230000029936 alkylation Effects 0.000 description 1
238000005804 alkylation reaction Methods 0.000 description 1
230000000172 allergic effect Effects 0.000 description 1
230000008856 allosteric binding Effects 0.000 description 1
230000003281 allosteric effect Effects 0.000 description 1
150000001371 alpha-amino acids Chemical class 0.000 description 1
125000003368 amide group Chemical group 0.000 description 1
229960003036 amisulpride Drugs 0.000 description 1
NTJOBXMMWNYJFB-UHFFFAOYSA-N amisulpride Chemical compound CCN1CCCC1CNC(=O)C1=CC(S(=O)(=O)CC)=C(N)C=C1OC NTJOBXMMWNYJFB-UHFFFAOYSA-N 0.000 description 1
KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 1
229910021529 ammonia Inorganic materials 0.000 description 1
230000003444 anaesthetic effect Effects 0.000 description 1
229940025141 anafranil Drugs 0.000 description 1
230000036592 analgesia Effects 0.000 description 1
238000010171 animal model Methods 0.000 description 1
229940124604 anti-psychotic medication Drugs 0.000 description 1
239000002249 anxiolytic agent Substances 0.000 description 1
230000000949 anxiolytic effect Effects 0.000 description 1
230000001640 apoptogenic effect Effects 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
229960003121 arginine Drugs 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
229960004372 aripiprazole Drugs 0.000 description 1
125000003118 aryl group Chemical group 0.000 description 1
229940072107 ascorbate Drugs 0.000 description 1
235000010323 ascorbic acid Nutrition 0.000 description 1
239000011668 ascorbic acid Substances 0.000 description 1
229960005245 asenapine Drugs 0.000 description 1
229960001230 asparagine Drugs 0.000 description 1
235000009582 asparagine Nutrition 0.000 description 1
208000010668 atopic eczema Diseases 0.000 description 1
230000037444 atrophy Effects 0.000 description 1
208000029560 autism spectrum disease Diseases 0.000 description 1
208000022804 avoidant personality disease Diseases 0.000 description 1
WBGBOXYJYPVLQJ-UHFFFAOYSA-N aziridine-2-carboxylic acid Chemical compound OC(=O)C1CN1 WBGBOXYJYPVLQJ-UHFFFAOYSA-N 0.000 description 1
150000007514 bases Chemical class 0.000 description 1
229940050390 benzoate Drugs 0.000 description 1
229920000249 biocompatible polymer Polymers 0.000 description 1
229920002988 biodegradable polymer Polymers 0.000 description 1
229960000074 biopharmaceutical Drugs 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
208000030963 borderline personality disease Diseases 0.000 description 1
125000001246 bromo group Chemical group Br* 0.000 description 1
SNPPWIUOZRMYNY-UHFFFAOYSA-N bupropion Chemical compound CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 SNPPWIUOZRMYNY-UHFFFAOYSA-N 0.000 description 1
DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 1
FFSAXUULYPJSKH-UHFFFAOYSA-N butyrophenone Chemical class CCCC(=O)C1=CC=CC=C1 FFSAXUULYPJSKH-UHFFFAOYSA-N 0.000 description 1
MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
150000001721 carbon Chemical group 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
125000002843 carboxylic acid group Chemical group 0.000 description 1
239000000969 carrier Substances 0.000 description 1
229940047493 celexa Drugs 0.000 description 1
230000030833 cell death Effects 0.000 description 1
230000002490 cerebral effect Effects 0.000 description 1
206010008129 cerebral palsy Diseases 0.000 description 1
230000008859 change Effects 0.000 description 1
229910052801 chlorine Inorganic materials 0.000 description 1
125000001309 chloro group Chemical group Cl* 0.000 description 1
CDCYQPLVFSUEBQ-WCCKRBBISA-N chloromethane (2S)-pyrrolidine-2-carboxylic acid Chemical compound CCl.N1[C@H](C(=O)O)CCC1 CDCYQPLVFSUEBQ-WCCKRBBISA-N 0.000 description 1
230000037326 chronic stress Effects 0.000 description 1
229940001468 citrate Drugs 0.000 description 1
229960004170 clozapine Drugs 0.000 description 1
QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
230000007422 cognition related pathway Effects 0.000 description 1
230000003920 cognitive function Effects 0.000 description 1
229920001436 collagen Polymers 0.000 description 1
238000002648 combination therapy Methods 0.000 description 1
239000002361 compost Substances 0.000 description 1
239000013256 coordination polymer Substances 0.000 description 1
229920001577 copolymer Polymers 0.000 description 1
239000012043 crude product Substances 0.000 description 1
238000002425 crystallisation Methods 0.000 description 1
230000008025 crystallization Effects 0.000 description 1
125000004122 cyclic group Chemical group 0.000 description 1
125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
229940029644 cymbalta Drugs 0.000 description 1
229960002433 cysteine Drugs 0.000 description 1
235000018417 cysteine Nutrition 0.000 description 1
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
230000006378 damage Effects 0.000 description 1
238000007405 data analysis Methods 0.000 description 1
230000001934 delay Effects 0.000 description 1
208000013257 developmental and epileptic encephalopathy Diseases 0.000 description 1
CSJLBAMHHLJAAS-UHFFFAOYSA-N diethylaminosulfur trifluoride Substances CCN(CC)S(F)(F)F CSJLBAMHHLJAAS-UHFFFAOYSA-N 0.000 description 1
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
229940043264 dodecyl sulfate Drugs 0.000 description 1
201000002545 drug psychosis Diseases 0.000 description 1
230000004064 dysfunction Effects 0.000 description 1
208000024732 dysthymic disease Diseases 0.000 description 1
229940098766 effexor Drugs 0.000 description 1
229940011681 elavil Drugs 0.000 description 1
238000000132 electrospray ionisation Methods 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
238000006911 enzymatic reaction Methods 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
239000005038 ethylene vinyl acetate Substances 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
230000003492 excitotoxic effect Effects 0.000 description 1
231100000063 excitotoxicity Toxicity 0.000 description 1
239000000284 extract Substances 0.000 description 1
206010016256 fatigue Diseases 0.000 description 1
238000005188 flotation Methods 0.000 description 1
239000006260 foam Substances 0.000 description 1
230000006870 function Effects 0.000 description 1
238000004817 gas chromatography Methods 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
239000011521 glass Substances 0.000 description 1
210000005046 glial fibrillary acidic protein Anatomy 0.000 description 1
229940050410 gluconate Drugs 0.000 description 1
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
229960002743 glutamine Drugs 0.000 description 1
229930182470 glycoside Natural products 0.000 description 1
150000002338 glycosides Chemical class 0.000 description 1
239000008187 granular material Substances 0.000 description 1
125000005843 halogen group Chemical group 0.000 description 1
231100000869 headache Toxicity 0.000 description 1
MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
125000005842 heteroatom Chemical group 0.000 description 1
125000000592 heterocycloalkyl group Chemical group 0.000 description 1
FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
230000000971 hippocampal effect Effects 0.000 description 1
210000001320 hippocampus Anatomy 0.000 description 1
229960002885 histidine Drugs 0.000 description 1
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
150000004677 hydrates Chemical class 0.000 description 1
229930195733 hydrocarbon Natural products 0.000 description 1
XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
KLGSHNXEUZOKHH-JBUOLDKXSA-N hydron;methyl (2s,4r)-4-hydroxypyrrolidine-2-carboxylate;chloride Chemical compound Cl.COC(=O)[C@@H]1C[C@@H](O)CN1 KLGSHNXEUZOKHH-JBUOLDKXSA-N 0.000 description 1
208000013403 hyperactivity Diseases 0.000 description 1
229960003162 iloperidone Drugs 0.000 description 1
XMXHEBAFVSFQEX-UHFFFAOYSA-N iloperidone Chemical compound COC1=CC(C(C)=O)=CC=C1OCCCN1CCC(C=2C3=CC=C(F)C=C3ON=2)CC1 XMXHEBAFVSFQEX-UHFFFAOYSA-N 0.000 description 1
XZZXIYZZBJDEEP-UHFFFAOYSA-N imipramine hydrochloride Chemical compound [Cl-].C1CC2=CC=CC=C2N(CCC[NH+](C)C)C2=CC=CC=C21 XZZXIYZZBJDEEP-UHFFFAOYSA-N 0.000 description 1
230000007813 immunodeficiency Effects 0.000 description 1
239000007943 implant Substances 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
230000036512 infertility Effects 0.000 description 1
230000004941 influx Effects 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
239000007972 injectable composition Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
208000014674 injury Diseases 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
125000002346 iodo group Chemical group I* 0.000 description 1
230000001057 ionotropic effect Effects 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
159000000014 iron salts Chemical class 0.000 description 1
208000028867 ischemia Diseases 0.000 description 1
SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
LSACYLWPPQLVSM-UHFFFAOYSA-N isobutyric acid anhydride Chemical compound CC(C)C(=O)OC(=O)C(C)C LSACYLWPPQLVSM-UHFFFAOYSA-N 0.000 description 1
229960000310 isoleucine Drugs 0.000 description 1
235000014705 isoleucine Nutrition 0.000 description 1
AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
TWBYWOBDOCUKOW-UHFFFAOYSA-M isonicotinate Chemical compound [O-]C(=O)C1=CC=NC=C1 TWBYWOBDOCUKOW-UHFFFAOYSA-M 0.000 description 1
239000007951 isotonicity adjuster Substances 0.000 description 1
HXEACLLIILLPRG-RXMQYKEDSA-N l-pipecolic acid Natural products OC(=O)[C@H]1CCCCN1 HXEACLLIILLPRG-RXMQYKEDSA-N 0.000 description 1
229940001447 lactate Drugs 0.000 description 1
239000000787 lecithin Substances 0.000 description 1
235000010445 lecithin Nutrition 0.000 description 1
229940067606 lecithin Drugs 0.000 description 1
229960003136 leucine Drugs 0.000 description 1
235000005772 leucine Nutrition 0.000 description 1
229940054157 lexapro Drugs 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
239000002502 liposome Substances 0.000 description 1
238000004811 liquid chromatography Methods 0.000 description 1
230000005923 long-lasting effect Effects 0.000 description 1
229960001432 lurasidone Drugs 0.000 description 1
PQXKDMSYBGKCJA-CVTJIBDQSA-N lurasidone Chemical compound C1=CC=C2C(N3CCN(CC3)C[C@@H]3CCCC[C@H]3CN3C(=O)[C@@H]4[C@H]5CC[C@H](C5)[C@@H]4C3=O)=NSC2=C1 PQXKDMSYBGKCJA-CVTJIBDQSA-N 0.000 description 1
229940009622 luvox Drugs 0.000 description 1
235000018977 lysine Nutrition 0.000 description 1
229960003646 lysine Drugs 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
229940049920 malate Drugs 0.000 description 1
BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
229940110127 marplan Drugs 0.000 description 1
238000004949 mass spectrometry Methods 0.000 description 1
239000012528 membrane Substances 0.000 description 1
230000006984 memory degeneration Effects 0.000 description 1
208000023060 memory loss Diseases 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
229930182817 methionine Natural products 0.000 description 1
229960004452 methionine Drugs 0.000 description 1
150000004702 methyl esters Chemical class 0.000 description 1
APCHKWZTSCBBJX-UHFFFAOYSA-N methyl piperidine-2-carboxylate;hydrochloride Chemical compound Cl.COC(=O)C1CCCCN1 APCHKWZTSCBBJX-UHFFFAOYSA-N 0.000 description 1
BQQZKNAQDKIGGZ-UHFFFAOYSA-N methyl piperidine-3-carboxylate;hydrochloride Chemical compound Cl.COC(=O)C1CCCNC1 BQQZKNAQDKIGGZ-UHFFFAOYSA-N 0.000 description 1
239000004530 micro-emulsion Substances 0.000 description 1
RONZAEMNMFQXRA-UHFFFAOYSA-N mirtazapine Chemical compound C1C2=CC=CN=C2N2CCN(C)CC2C2=CC=CC=C21 RONZAEMNMFQXRA-UHFFFAOYSA-N 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
125000002950 monocyclic group Chemical group 0.000 description 1
230000004973 motor coordination Effects 0.000 description 1
230000035772 mutation Effects 0.000 description 1
KVBGVZZKJNLNJU-UHFFFAOYSA-M naphthalene-2-sulfonate Chemical compound C1=CC=CC2=CC(S(=O)(=O)[O-])=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-M 0.000 description 1
229940087524 nardil Drugs 0.000 description 1
230000008693 nausea Effects 0.000 description 1
230000008764 nerve damage Effects 0.000 description 1
210000000653 nervous system Anatomy 0.000 description 1
210000003061 neural cell Anatomy 0.000 description 1
230000001537 neural effect Effects 0.000 description 1
208000015122 neurodegenerative disease Diseases 0.000 description 1
230000007472 neurodevelopment Effects 0.000 description 1
201000004931 neurofibromatosis Diseases 0.000 description 1
230000000926 neurological effect Effects 0.000 description 1
210000002569 neuron Anatomy 0.000 description 1
230000000324 neuroprotective effect Effects 0.000 description 1
230000003472 neutralizing effect Effects 0.000 description 1
235000001968 nicotinic acid Nutrition 0.000 description 1
239000011664 nicotinic acid Substances 0.000 description 1
125000004433 nitrogen atom Chemical group N* 0.000 description 1
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
239000012457 nonaqueous media Substances 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
229940087480 norpramin Drugs 0.000 description 1
239000002674 ointment Substances 0.000 description 1
229960005017 olanzapine Drugs 0.000 description 1
KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 description 1
229940049964 oleate Drugs 0.000 description 1
ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
201000005040 opiate dependence Diseases 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
125000004430 oxygen atom Chemical group O* 0.000 description 1
230000037324 pain perception Effects 0.000 description 1
229960001057 paliperidone Drugs 0.000 description 1
229940055692 pamelor Drugs 0.000 description 1
WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
229940014662 pantothenate Drugs 0.000 description 1
235000019161 pantothenic acid Nutrition 0.000 description 1
239000011713 pantothenic acid Substances 0.000 description 1
229940087824 parnate Drugs 0.000 description 1
229960002296 paroxetine Drugs 0.000 description 1
239000002245 particle Substances 0.000 description 1
239000006072 paste Substances 0.000 description 1
210000001428 peripheral nervous system Anatomy 0.000 description 1
JRKICGRDRMAZLK-UHFFFAOYSA-L peroxydisulfate Chemical compound [O-]S(=O)(=O)OOS([O-])(=O)=O JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 description 1
208000022821 personality disease Diseases 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
229950010883 phencyclidine Drugs 0.000 description 1
125000001484 phenothiazinyl group Chemical class C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 description 1
DYUMLJSJISTVPV-UHFFFAOYSA-N phenyl propanoate Chemical compound CCC(=O)OC1=CC=CC=C1 DYUMLJSJISTVPV-UHFFFAOYSA-N 0.000 description 1
229960005190 phenylalanine Drugs 0.000 description 1
COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
239000002953 phosphate buffered saline Substances 0.000 description 1
HXEACLLIILLPRG-UHFFFAOYSA-N pipecolic acid Chemical compound OC(=O)C1CCCCN1 HXEACLLIILLPRG-UHFFFAOYSA-N 0.000 description 1
229950010765 pivalate Drugs 0.000 description 1
IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
229920000747 poly(lactic acid) Polymers 0.000 description 1
229920000728 polyester Polymers 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
239000004633 polyglycolic acid Substances 0.000 description 1
239000004626 polylactic acid Substances 0.000 description 1
239000004926 polymethyl methacrylate Substances 0.000 description 1
229920005862 polyol Polymers 0.000 description 1
150000003077 polyols Chemical class 0.000 description 1
239000011148 porous material Substances 0.000 description 1
239000011591 potassium Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
210000002442 prefrontal cortex Anatomy 0.000 description 1
108010074732 preproenkephalin Proteins 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
230000000750 progressive effect Effects 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
230000017854 proteolysis Effects 0.000 description 1
OGQDIIKRQRZXJH-UHFFFAOYSA-N protriptyline hydrochloride Chemical compound [Cl-].C1=CC2=CC=CC=C2C(CCC[NH2+]C)C2=CC=CC=C21 OGQDIIKRQRZXJH-UHFFFAOYSA-N 0.000 description 1
229940035613 prozac Drugs 0.000 description 1
239000002510 pyrogen Substances 0.000 description 1
229960004431 quetiapine Drugs 0.000 description 1
URKOMYMAXPYINW-UHFFFAOYSA-N quetiapine Chemical compound C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 URKOMYMAXPYINW-UHFFFAOYSA-N 0.000 description 1
229940044601 receptor agonist Drugs 0.000 description 1
239000000018 receptor agonist Substances 0.000 description 1
229940075993 receptor modulator Drugs 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
229940023942 remeron Drugs 0.000 description 1
239000003340 retarding agent Substances 0.000 description 1
238000004007 reversed phase HPLC Methods 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
229960001534 risperidone Drugs 0.000 description 1
RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 description 1
YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
229960001860 salicylate Drugs 0.000 description 1
239000000523 sample Substances 0.000 description 1
238000009738 saturating Methods 0.000 description 1
230000001932 seasonal effect Effects 0.000 description 1
229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 1
239000012896 selective serotonin reuptake inhibitor Substances 0.000 description 1
229910052711 selenium Inorganic materials 0.000 description 1
238000000926 separation method Methods 0.000 description 1
229960001153 serine Drugs 0.000 description 1
GZKLJWGUPQBVJQ-UHFFFAOYSA-N sertindole Chemical compound C1=CC(F)=CC=C1N1C2=CC=C(Cl)C=C2C(C2CCN(CCN3C(NCC3)=O)CC2)=C1 GZKLJWGUPQBVJQ-UHFFFAOYSA-N 0.000 description 1
229960000652 sertindole Drugs 0.000 description 1
VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 description 1
208000013220 shortness of breath Diseases 0.000 description 1
230000019491 signal transduction Effects 0.000 description 1
229910052710 silicon Inorganic materials 0.000 description 1
239000010703 silicon Substances 0.000 description 1
230000007958 sleep Effects 0.000 description 1
230000000391 smoking effect Effects 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
239000012321 sodium triacetoxyborohydride Substances 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
238000013222 sprague-dawley male rat Methods 0.000 description 1
239000007921 spray Substances 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
239000008174 sterile solution Substances 0.000 description 1
230000001954 sterilising effect Effects 0.000 description 1
238000004659 sterilization and disinfection Methods 0.000 description 1
238000003860 storage Methods 0.000 description 1
230000035882 stress Effects 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
239000000758 substrate Substances 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
150000005846 sugar alcohols Polymers 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
229910052717 sulfur Inorganic materials 0.000 description 1
239000011593 sulfur Substances 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
229940118176 surmontil Drugs 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
238000010189 synthetic method Methods 0.000 description 1
239000003826 tablet Substances 0.000 description 1
WWJZWCUNLNYYAU-UHFFFAOYSA-N temephos Chemical compound C1=CC(OP(=S)(OC)OC)=CC=C1SC1=CC=C(OP(=S)(OC)OC)C=C1 WWJZWCUNLNYYAU-UHFFFAOYSA-N 0.000 description 1
125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
BCWUGEIFXRKYMP-UHFFFAOYSA-N tert-butyl 1-oxo-2,8-diazaspiro[5.5]undecane-8-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCCC11C(=O)NCCC1 BCWUGEIFXRKYMP-UHFFFAOYSA-N 0.000 description 1
HBBXYZBTVSFELH-UHFFFAOYSA-N tert-butyl 10-benzyl-11-oxo-1,10-diazaspiro[4.6]undec-7-ene-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCCC11CC=CCN(CC2=CC=CC=C2)C1=O HBBXYZBTVSFELH-UHFFFAOYSA-N 0.000 description 1
NQSRGDMKYRGVHK-UHFFFAOYSA-N tert-butyl 10-oxo-1,9-diazaspiro[4.5]decane-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCCC11C(=O)NCCC1 NQSRGDMKYRGVHK-UHFFFAOYSA-N 0.000 description 1
QWCXBLQWNBBXCP-UHFFFAOYSA-N tert-butyl 11-oxo-1,10-diazaspiro[4.6]undec-7-ene-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCCC11CC=CCNC1=O QWCXBLQWNBBXCP-UHFFFAOYSA-N 0.000 description 1
MXUMAJXWRVMNPH-UHFFFAOYSA-N tert-butyl 12-oxo-1,11-diazaspiro[5.6]dodec-8-ene-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCCCC11CC=CCNC1=O MXUMAJXWRVMNPH-UHFFFAOYSA-N 0.000 description 1
NOFXHWOWJRJWCK-UHFFFAOYSA-N tert-butyl 12-oxo-1,11-diazaspiro[5.6]dodecane-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCCCC11CCCCNC1=O NOFXHWOWJRJWCK-UHFFFAOYSA-N 0.000 description 1
JXDVMKQFPSVLBZ-UHFFFAOYSA-N tert-butyl 6-oxo-1,7-diazaspiro[4.4]nonane-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCCC11C(=O)NCC1 JXDVMKQFPSVLBZ-UHFFFAOYSA-N 0.000 description 1
NFCRQDOCGHYPRW-UHFFFAOYSA-N tert-butyl 7-oxo-1,8-diazaspiro[5.5]undecane-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCCCC11C(=O)NCCC1 NFCRQDOCGHYPRW-UHFFFAOYSA-N 0.000 description 1
OOPZEUYAKBMPDZ-UHFFFAOYSA-N tert-butyl 7-oxo-2,8-diazaspiro[5.6]dodecane-2-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCCC21C(=O)NCCCC2 OOPZEUYAKBMPDZ-UHFFFAOYSA-N 0.000 description 1
125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
108091008646 testicular receptors Proteins 0.000 description 1
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
230000004797 therapeutic response Effects 0.000 description 1
229960002898 threonine Drugs 0.000 description 1
229940041597 tofranil Drugs 0.000 description 1
125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
PMMYEEVYMWASQN-IMJSIDKUSA-N trans-4-Hydroxy-L-proline Natural products O[C@@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-IMJSIDKUSA-N 0.000 description 1
238000000844 transformation Methods 0.000 description 1
230000000472 traumatic effect Effects 0.000 description 1
230000008736 traumatic injury Effects 0.000 description 1
229960003991 trazodone Drugs 0.000 description 1
239000003029 tricyclic antidepressant agent Substances 0.000 description 1
125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
YDGHCKHAXOUQOS-BTJKTKAUSA-N trimipramine maleate Chemical compound [O-]C(=O)\C=C/C([O-])=O.C1CC2=CC=CC=C2[NH+](CC(C[NH+](C)C)C)C2=CC=CC=C21 YDGHCKHAXOUQOS-BTJKTKAUSA-N 0.000 description 1
229960004799 tryptophan Drugs 0.000 description 1
229960004441 tyrosine Drugs 0.000 description 1
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
ZDPHROOEEOARMN-UHFFFAOYSA-N undecanoic acid Chemical compound CCCCCCCCCCC(O)=O ZDPHROOEEOARMN-UHFFFAOYSA-N 0.000 description 1
238000001291 vacuum drying Methods 0.000 description 1
238000009777 vacuum freeze-drying Methods 0.000 description 1
229960004295 valine Drugs 0.000 description 1
239000004474 valine Substances 0.000 description 1
PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 description 1
230000031836 visual learning Effects 0.000 description 1
229940045977 vivactil Drugs 0.000 description 1
229940009065 wellbutrin Drugs 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1
239000002023 wood Substances 0.000 description 1
229910052725 zinc Inorganic materials 0.000 description 1
239000011701 zinc Substances 0.000 description 1
229960000607 ziprasidone Drugs 0.000 description 1
MVWVFYHBGMAFLY-UHFFFAOYSA-N ziprasidone Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=4CC(=O)NC=4C=C3Cl)=NSC2=C1 MVWVFYHBGMAFLY-UHFFFAOYSA-N 0.000 description 1
229940020965 zoloft Drugs 0.000 description 1
229960004496 zotepine Drugs 0.000 description 1
HDOZVRUNCMBHFH-UHFFFAOYSA-N zotepine Chemical compound CN(C)CCOC1=CC2=CC=CC=C2SC2=CC=C(Cl)C=C12 HDOZVRUNCMBHFH-UHFFFAOYSA-N 0.000 description 1